ProxyMiner / Company

RESMED INCRMD

Latest proxy: 2025 · view on SEC ↗ · CIK 0000943819

CEO total pay

$14,674,543

Michael Farrell · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

Item 402(u)

187 to 1

Median employee: $14,674,543

Compensation committee

CD&A

Compensation and Leadership Development Committee

Per the latest proxy

Filings indexed: 2 · 2025 · 2024

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Michael Farrell2025 compensation
Chief executive officer
$14,674,543↑ 4%
91% at-risk
$1,214,150$8,775,059$1,646,743$113,584
Brett Sandercock2025 compensation
Chief financial officer
$3,572,010↑ 10%
84% at-risk
$498,967$2,600,037$407,171$65,835
Justin Leong2025 compensation
Chief product officer
$3,911,441
81% at-risk
$677,032$2,600,037$552,478$81,894
Bobby Ghoshal2025 compensation
Chief commercial officer, Residential Care Software
$3,652,455↑ 3%
81% at-risk
$651,660$2,400,078$550,001$50,716
Mike Rider2025 compensation
Named executive officer
$2,289,122
75% at-risk
$508,745$1,400,005$311,363$69,009

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

Executive Summary 2025 Performance Highlights During fiscal year 2025, Resmed confronted a challenging operating environment—marked by diagnostic bottlenecks, trade disruption, and the emergence of new pharmaceutical treatment alternatives for patients with obstructive sleep apnea and obesity—with resilience and discipline. Our teams responded swiftly and strategically, delivering strong financial outcomes and meaningful progress across our business. Challenges this year included: •Persistent delays in patient throughput caused by provider and lab constraints; and •Macroeconomic volatility and trade disruption that pressured logistics and sourcing. Our strategic response: •Intensified operational execution, balancing cost discipline with delivery excellence; •Invested in demand stimulation and capture through marketing, provider engagement, and digital channels; and •Deepened our digital health ecosystem via innovation and targeted acquisitions, expanding access and engagement beyond the device into software‑enabled care. Results achieved in FY25: •Double‑digit revenue and EPS growth, while driving expanding gross and operating margins; •Significant uptake of digital health solutio…

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • hedging

    prohibited

    “Pledging and hedging prohibited”

  • pledging

    prohibited

    “Pledging and hedging prohibited”

  • clawback

    present

    “Clawback Policy”

  • stock ownership guidelines

    present

    “stock ownership guidelines, requiring our chief executive officer to hold stock valued at 600% of salary and our other named executive officers to hold stock valued at 300% of salary”

  • change in control

    Change of Control Agreements

    “Change of Control Agreements”

  • compensation consultant

    independent

    “independent compensation consultant.”

  • compensation committee

    Compensation and Leadership Development Committee

    “Compensation and Leadership Development Committee”

Performance markers

Metric facts

  • revenue

    $4.720

    “in our sales along with improvement in our operating profit created by procurement, manufacturing and logistics efficiencies in fiscal year 2025. Our fiscal year 2025 adjusted net sales (adjusted for committee-approved p…”

  • annual incentive payout

    106.28%

    “*Adjustments to actual performance under the 2025 cash incentive plan are set forth under “Incentive Plan Adjustments.””

  • performance equity mix

    50%

    “For fiscal year 2025, we continued our policy of allowing our named executive officers the choice of whether to receive all options, all performance-based RSUs, or a 50:50 split of the two award types for the 50% of thei…”

  • ceo pay ratio

    187 to 1

    “determining this pay ratio was $14,674,543. The annual total compensation of the median employee and the annual total compensation of the chief executive officer were calculated in accordance with the requirements of Ite…”

  • median employee compensation

    $14,674,543

    “and target incentive payments, due to turnover. The annual total compensation of the median employee for the fiscal year ending June 30, 2025, was $78,354; and the annual total compensation of our chief executive officer…”

Ask

Anything about RESMED INC’s 2025 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…